



Association of British Neurologists

Programme of the Annual Meeting

3-5 May 2017

ACC Liverpool

Annual Sponsors for 2017:

Biogen Idec, Roche, Novartis, Teva UK, Merck

Wednesday 3 May			
09:00	Opening and Welcome		
09:15	Plenary session 1 Setting a precise treatment course: Personalised medicine in neurology Personalised medicine- the contribution of genetics and genomics: Patrick Chinnery, Cambridge How close are we to personalised medicine for neurological disease? Kevin Talbot, Oxford Pharmacogenetics - its relevance to the neurologist: Munir Pirmohamed, Liverpool		
10:45	Coffee & Exhibition 1		
11:15	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; vertical-align: top;"> Platform 1- Pathophysiology 1 <ul style="list-style-type: none"> Chronic traumatic encephalopathy in retired footballers with dementia Autonomic and cognitive impairment after traumatic brain injury Epidural Stimulation of the Ventral and Dorsal Cervical Spinal Cord Ethnic Minority Outcomes in Multiple Sclerosis How common is truly benign MS? Japanese encephalitis epidemic in northeast India: 45 cases </td> <td style="width: 50%; vertical-align: top;"> Platform 2- Clinical effectiveness <ul style="list-style-type: none"> Applying the 2015 Neuromyelitis optica criteria in clinical practice Pregnancy Outcomes in Alemtuzumab Trials and Registry Design How effective is rituximab in NMO? A review of 50 patients Patients' preferences for anti-epileptic drugs (AEDs) Does slow escalation of steroid dose reduce the risk of deterioration in patients with a myasthenic crisis? Undertreatment of vascular risk factors in patients presenting with ischaemic ocular events: results from 395 patients in a tertiary centre </td> </tr> </table>	Platform 1- Pathophysiology 1 <ul style="list-style-type: none"> Chronic traumatic encephalopathy in retired footballers with dementia Autonomic and cognitive impairment after traumatic brain injury Epidural Stimulation of the Ventral and Dorsal Cervical Spinal Cord Ethnic Minority Outcomes in Multiple Sclerosis How common is truly benign MS? Japanese encephalitis epidemic in northeast India: 45 cases 	Platform 2- Clinical effectiveness <ul style="list-style-type: none"> Applying the 2015 Neuromyelitis optica criteria in clinical practice Pregnancy Outcomes in Alemtuzumab Trials and Registry Design How effective is rituximab in NMO? A review of 50 patients Patients' preferences for anti-epileptic drugs (AEDs) Does slow escalation of steroid dose reduce the risk of deterioration in patients with a myasthenic crisis? Undertreatment of vascular risk factors in patients presenting with ischaemic ocular events: results from 395 patients in a tertiary centre
Platform 1- Pathophysiology 1 <ul style="list-style-type: none"> Chronic traumatic encephalopathy in retired footballers with dementia Autonomic and cognitive impairment after traumatic brain injury Epidural Stimulation of the Ventral and Dorsal Cervical Spinal Cord Ethnic Minority Outcomes in Multiple Sclerosis How common is truly benign MS? Japanese encephalitis epidemic in northeast India: 45 cases 	Platform 2- Clinical effectiveness <ul style="list-style-type: none"> Applying the 2015 Neuromyelitis optica criteria in clinical practice Pregnancy Outcomes in Alemtuzumab Trials and Registry Design How effective is rituximab in NMO? A review of 50 patients Patients' preferences for anti-epileptic drugs (AEDs) Does slow escalation of steroid dose reduce the risk of deterioration in patients with a myasthenic crisis? Undertreatment of vascular risk factors in patients presenting with ischaemic ocular events: results from 395 patients in a tertiary centre 		
12:30	Lunch, Exhibition		
12:30	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; text-align: center;">Novartis - The Burden of Migraine and Progression Towards New Treatments</td> <td style="width: 50%; text-align: center;">Teva UK - Optimising management for family planning in MS: Strategies for an on-going challenge</td> </tr> </table>	Novartis - The Burden of Migraine and Progression Towards New Treatments	Teva UK - Optimising management for family planning in MS: Strategies for an on-going challenge
Novartis - The Burden of Migraine and Progression Towards New Treatments	Teva UK - Optimising management for family planning in MS: Strategies for an on-going challenge		
14:00	Gordon Holmes lecture: Eric Hoffman, Binghampton University, USA Title: Duchenne's Muscular dystrophy - from gene discovery to treatment		
14:45	Poster session with discussants 1		
15:45	Coffee & Exhibition 2 ABNT Forum		
16:15	Practical Neurology lecture: Andrew Schwartz, University of Pittsburgh, USA Title: 'Recent progress toward high-performance neural prosthetics'		
17:00	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; vertical-align: top;"> Platform 3- Diagnostics <ul style="list-style-type: none"> Acute Neurology Service: 'Who should be seen and when?' Use of next-generation sequencing in heterogenous dementia referrals MRI-Analysis in Patients with 'non-lesional' Epilepsy Diagnostic Classification of Lower Motor Neuron Disorders Screening for monogenic cerebral small vessel disease using whole genome sequencing Brain and carotid MRI for stroke prediction in symptomatic carotid artery disease </td> <td style="width: 50%; vertical-align: top;"> Platform 4- Disease management <ul style="list-style-type: none"> Clinical phenotype and outcome of hepatitis E virus associated neuralgic amyotrophy (HEV-NA); an international multicentre retrospective comparative study "Less contented as a person": preliminary data from the LGI1-QoL study PCP prophylaxis in neurology - A review of the incidence of opportunistic infection in patients with myasthenia gravis Development and validation of Spasticity Index - Amyotrophic lateral sclerosis (SI-ALS) Antiepileptic drug monotherapy: a network meta-analysis of 10 AEDs UK Unscheduled Admissions for Adults with Suspected Seizures </td> </tr> </table>	Platform 3- Diagnostics <ul style="list-style-type: none"> Acute Neurology Service: 'Who should be seen and when?' Use of next-generation sequencing in heterogenous dementia referrals MRI-Analysis in Patients with 'non-lesional' Epilepsy Diagnostic Classification of Lower Motor Neuron Disorders Screening for monogenic cerebral small vessel disease using whole genome sequencing Brain and carotid MRI for stroke prediction in symptomatic carotid artery disease 	Platform 4- Disease management <ul style="list-style-type: none"> Clinical phenotype and outcome of hepatitis E virus associated neuralgic amyotrophy (HEV-NA); an international multicentre retrospective comparative study "Less contented as a person": preliminary data from the LGI1-QoL study PCP prophylaxis in neurology - A review of the incidence of opportunistic infection in patients with myasthenia gravis Development and validation of Spasticity Index - Amyotrophic lateral sclerosis (SI-ALS) Antiepileptic drug monotherapy: a network meta-analysis of 10 AEDs UK Unscheduled Admissions for Adults with Suspected Seizures
Platform 3- Diagnostics <ul style="list-style-type: none"> Acute Neurology Service: 'Who should be seen and when?' Use of next-generation sequencing in heterogenous dementia referrals MRI-Analysis in Patients with 'non-lesional' Epilepsy Diagnostic Classification of Lower Motor Neuron Disorders Screening for monogenic cerebral small vessel disease using whole genome sequencing Brain and carotid MRI for stroke prediction in symptomatic carotid artery disease 	Platform 4- Disease management <ul style="list-style-type: none"> Clinical phenotype and outcome of hepatitis E virus associated neuralgic amyotrophy (HEV-NA); an international multicentre retrospective comparative study "Less contented as a person": preliminary data from the LGI1-QoL study PCP prophylaxis in neurology - A review of the incidence of opportunistic infection in patients with myasthenia gravis Development and validation of Spasticity Index - Amyotrophic lateral sclerosis (SI-ALS) Antiepileptic drug monotherapy: a network meta-analysis of 10 AEDs UK Unscheduled Admissions for Adults with Suspected Seizures 		
18:15	Late breaking news		
18:35	Drinks reception and posters		

Thursday 4 May					
07:00	FUN RUN - 5KM				
07:45	SIG 1: Epilepsy 1C	SIG 2: Movement disorders 1B	SIG 3: Peripheral nerve 1C	SIG 4: Autonomic 7	SIG 5: Myology 10
09:00	Plenary session 2 Navigating new mechanisms & treatments in neurodegeneration: Prion disease beyond prion disease: John Collinge, London Treatment trials in dementia: Cath Mummery, London New approaches in Huntington's disease- what have we learnt: Anne Rosser, Cardiff				
10:30	Coffee and Exhibition 3				
11:00	AGM				
12:10	Poster session with discussants 2				
13:10	Lunch, Exhibition Merck Serono - The lymphocyte journey in Multiple Sclerosis – <i>from a Disease Modifying Treatment perspective</i>				
14:40	ABN Medallist lecture: Martin Rossor Title: New words for old Citation: Nick Fox Chair: Phil Smith				
15:25	Coffee and Exhibition 4				
15:55	Business Session <ul style="list-style-type: none"> The new Neurosciences NNAG and CRG: Adrian Williams, Chair NNAG and CRG. Acute Neurology survey 2017 British Neurological Surveillance Unit: Rustam Al-Shahi Salman, Chair BNSU World Federation Neurology: Raad Shakir, President 		Platform 5 - Pathophysiology 2 <ul style="list-style-type: none"> Topiramate is as effective as Acetazolamide at lowering intracranial pressure in healthy rodents. Alterations in cerebral blood flow during the postdrome phase of a migraine attack captured with Arterial Spin Labelled (ASL) MRI Length of white matter connections determine their rate of atrophy in premanifest Huntington's disease Human sensory neuron co-cultures to model inflammatory neuropathy Linear- versus conformational-protein directed autoantibodies in neuropsychiatric systemic lupus erythematosus VGKC is dead: long live LGI1- and CASPR2-antibodies. Intracellular and non-neuronal targets of voltage-gated potassium channel complex antibodies 		
17:10	SIG 6: MS and neuroinflammation 1A	SIG 7: Functional disorders 1B	SIG 8: Neuroinfection 1C	SIG 9: Neurocritical care 7	SIG 10: British Neurotoxin Network 10
19:00	Gala Dinner: Liverpool Anglican Cathedral				

Friday 5 May

07:45	SIG 11: Neuro-ophthalmology 1A	SIG 12: Cognitive disorders 1B	SIG 13: Myasthenia Gravis 1C	SIG 14: Motor Neurone Disease 7	Traumatic Brain Injury 10
09:00	Case presentation competition				
10:15	President's lecture Life at the Periphery: Mary Reilly				
11:00	Coffee and Exhibition 5				
11:30	Plenary session 3 Global challenges in neuroinfection Encephalitis- a global issue: Tom Solomon, Liverpool CNS Tuberculosis in 2017 & the challenge of drug resistance: Onn Min Kon, London Neurological Montezuma's revenge: Hadi Manji, London				
13:00	Roche – A debate: 'Should the 2013 Lublin criteria become the mainstay of the UK MS treatment paradigm'	Lunch, Exhibition	Top 6 posters – Tom Warner		
14:30	Plenary session 4 "To boldly go..." innovative developments in neuroscience Clot retrieval for stroke: Phil White, Newcastle Stem cells as treatment: Roger Barker, Cambridge Innovative approaches to peripheral nerve and plexus damage: Anthony MacQuillan, RNOH				
16:00	Clinicopathological Conference Chair: Case presenters: Discussant: Richard Davenport				
16:45	Prize presentations and close				